BioNTech SE logo

BNTX - BioNTech SE News Story

$151.54 10.8  7.7%

Last Trade - 9:00pm

Sector
Healthcare
Size
Large Cap
Market Cap £24.65bn
Enterprise Value £23.69bn
Revenue £418.6m
Position in Universe 381st / 6851

Waiving patents alone won't solve COVID-19 vaccine access - developers

Mon 8th March, 2021 5:23pm
GENEVA, March 8 (Reuters) - Waiving intellectual property
rights will not be enough to resolve COVID-19 vaccine access
issues, the developers of the Oxford/Astrazeneca and the
Pfizer/BioNTech vaccines said on Monday, ahead of a meeting on
the topic at the World Trade Organization this week.
 urn:newsml:reuters.com:*:nL5N2L22NF
    "I don't think just making IP fully available goes anywhere
close to solving the problem...," said the University of Oxford
professor Sarah Gilbert at a World Health Organization virtual
press conference.
    BioNTech's Chief Medical Officer Dr Özlem Türeci said at the
same briefing: "Patents are one thing, but there are so many
other things we have to ensure."

 (Reporting by Emma Farge, Silke Koltrowitz and Toby Chopra;
Editing by Hugh Lawson)
 ((emma.farge@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.